PIA
RVNC

Phoenix Investment Adviser’s Revance Therapeutics, Inc. RVNC Stock Holding History

Phoenix Investment Adviser’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,900
Closed -$77K – 43
2019
Q1 		$77K Buy
4,900
+2,500
+104% +$43.4K 0.17% 29
2018
Q4 		$48K Hold
2,400
– – 0.1% 27
2018
Q3 		$60K Hold
2,400
– – 0.08% 38
2018
Q2 		$66K Buy
+2,400
New +$72.1K 0.12% 35

Other funds holding RVNC

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Phoenix Investment Adviser's RVNC Position: Q2 2019 in Review

Phoenix Investment Adviser sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2019, closing a stake of 4,900 shares — an estimated $77K sold.

Phoenix Investment Adviser first reported a position in RVNC in Q2 2018 and held it in 4 quarters. The position peaked at $77K in Q1 2019. 114 funds tracked by Wall St. Rank hold RVNC as of Q2 2019.

  • Phoenix Investment Adviser reported no remaining Revance Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Phoenix Investment Adviser sold 4,900 Revance Therapeutics, Inc. shares in Q2 2019, an estimated $77K.
  • Phoenix Investment Adviser first reported a position in Revance Therapeutics, Inc. in Q2 2018 and held it in 4 quarters.
  • Phoenix Investment Adviser's Revance Therapeutics, Inc. position peaked at $77K in Q1 2019.
  • 114 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2019.

Based on Phoenix Investment Adviser's 13F filing for Q2 2019, filed 12 Aug 2019.